Adolescent non-adherence reveals a genetic cause for diabetes

Diabetic Medicine

Volumn 32, Issue 6, 2015, Pages e20-e23

  Carmody, D ^a   Lindauer, K L ^a   Naylor, R N ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOKINASE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; GERMINAL CENTER KINASES; PROTEIN SERINE THREONINE KINASE;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIET RESTRICTION; DISEASE COURSE; GENE MUTATION; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ADOLESCENT BEHAVIOR; BLOOD; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 2; DIFFERENTIAL DIAGNOSIS; GENETICS; MEDICATION COMPLIANCE; PHYSIOLOGY; PRESCHOOL CHILD; SIBLING;

ADOLESCENT; ADOLESCENT BEHAVIOR; CHILD, PRESCHOOL; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; HUMANS; INSULIN; MALE; MEDICATION ADHERENCE; PROTEIN-SERINE-THREONINE KINASES; SIBLINGS;

EID: 84929429623     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12669     Document Type: Article

References (18)

1. Byrne MM, Sturis J, Clément K, Vionnet N, Pueyo ME, Stoffel M et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994; 93: 1120-1130.
2. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009; 30: 1512-1526.
3. Patterson CC, Gyürüs E, Rosenbauer J, Cinek O, Neu A, Schober E et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012; 55: 2142-2147.
4. Hekkala A, Knip M, Veijola R. Ketoacidosis at diagnosis of type 1 diabetes in children in northern Finland: temporal changes over 20 years. Diabetes Care 2007; 30: 861-866.
5. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320: 550-554.
6. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
7. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34: 1878-1884.
8. Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75: 422-426.
9. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
10. Chakera AJ, Spyer G, Vincent N, Ellard S, Hattersley AT, Dunne FP. The 0.1% of the population with glucokinase monogenic diabetes can be recognized by clinical characteristics in pregnancy: the Atlantic Diabetes in Pregnancy Cohort. Diabetes Care 2014 Feb 18.
11. Pihoker C, Gilliam LK, Ellard S, Dabelea D, Davis C, Dolan LM et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 2013; 98: 4055-4062.
12. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014; 311: 279-286.
13. Stride A, Shields B, Gill-Carey O, Chakera AJ, Colclough K, Ellard S et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 2014; 57: 54-56.
14. Naylor RN, John PM, Winn AN, Carmody D, Greeley SAW, Philipson LH et al. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care 2014; 37: 202-209.
15. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at www.genome.gov/sequencingcosts. Last accessed 1 August 2014.
16. Lorini R, Klersy C, d'Annunzio G, Massa O, Minuto N, Iafusco D et al. Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. Diabetes Care 2009; 32: 1864-1866
17. Vionnet N, Stoffel M, Takeda J, Yasuda K, Bell GI, Zouali H et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356(6371): 721-722.
18. Besser REJ, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011; 34: 286-291.